Reata Pharmaceuticals, Inc. Class A Common Stock

RETA

市值 US$65.7億

關於： Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

員工： 323